Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity

Shelley Day; Annis M. Rainey; Clio A. Harper

doi:10.3928/23258160-20161219-11

Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity

Shelley Day, Annis M. Rainey, Clio A. Harper

Resultado de la investigación: Article › revisión exhaustiva

9 Citas (Scopus)

Resumen

A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.

Idioma original	English (US)
Páginas (desde-hasta)	75-78
Número de páginas	4
Publicación	Ophthalmic Surgery Lasers and Imaging Retina
Volumen	48
N.º	1
DOI	https://doi.org/10.3928/23258160-20161219-11
Estado	Published - ene 2017
Publicado de forma externa	Sí

ASJC Scopus subject areas

Surgery
Ophthalmology

Acceder al documento

10.3928/23258160-20161219-11

Otros archivos y enlaces

Citar esto

@article{24a3113bd53b4c55b65b5c796a67a43e,

title = "Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity",

abstract = "A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.",

author = "Shelley Day and Rainey, {Annis M.} and Harper, {Clio A.}",

year = "2017",

month = jan,

doi = "10.3928/23258160-20161219-11",

language = "English (US)",

volume = "48",

pages = "75--78",

journal = "Ophthalmic Surgery",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "1",

}

TY - JOUR

T1 - Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity

AU - Day, Shelley

AU - Rainey, Annis M.

AU - Harper, Clio A.

PY - 2017/1

Y1 - 2017/1

N2 - A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.

AB - A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85012935331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012935331&partnerID=8YFLogxK

U2 - 10.3928/23258160-20161219-11

DO - 10.3928/23258160-20161219-11

M3 - Article

C2 - 28060398

AN - SCOPUS:85012935331

SN - 2325-8160

VL - 48

SP - 75

EP - 78

JO - Ophthalmic Surgery

JF - Ophthalmic Surgery

IS - 1

ER -

Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto